Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ:VANI)

0.9700 -0.0500 (-4.90%)
Streaming Delayed Price Updated: 12:35 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vivani Medical, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Vivani Medical Inc (NASDAQ:VANI) Reports Q4 2025 Results, Advances Semaglutide Implant to Phase 1 ↗
Via Chartmill
News headline image
Vivani Medical, Inc. Announces Closing of Common Stock Offering
From Vivani Medical, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Wednesday? ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Discover the top movers in Wednesday's pre-market session. ↗
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data ↗
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs ↗
Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions. 
Via Benzinga
News headline image
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars ↗
The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that... 
Via Stocktwits
News headline image
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing ↗
Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management. 
Via Benzinga
News headline image
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
From Vivani Medical, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025. 
Via Benzinga
News headline image
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
From Vivani Medical, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value ↗
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants. 
Via Benzinga
News headline image
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia ↗
Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology. 
Via Benzinga
News headline image
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia ↗
Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected... 
Via Benzinga
News headline image
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity ↗
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is... 
Via Benzinga
News headline image
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Vivani Medical, Inc.
Via Business Wire
News headline image
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024 ↗
VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.